Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 13/20 | 0.71 |
| ▸ | KRAS | P01116 | 7/20 | 0.71 |
| ▸ | EGFR | P00533 | 7/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.53 |
| ▸ | FBP1 | P09467 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27041247 | 1.00 | SOS1 (0.71) | SOS1KRASEGFRHDAC3HDAC4 | |
| SCHEMBL29486868 | 0.94 | SOS1 (0.70) | SOS1KRASEGFRHDAC3HDAC4 | |
| SCHEMBL29985093 | 0.92 | SOS1 (0.65) | SOS1KRASEGFRHDAC3HDAC4 | |
| SCHEMBL29985070 | 0.92 | SOS1 (0.64) | SOS1KRASEGFRHDAC3HDAC4 | |
| SCHEMBL27041231 | 0.91 | SOS1 (0.70) | SOS1KRASEGFRHDAC3HDAC4 | |
| SCHEMBL29486842 | 0.91 | SOS1 (0.72) | SOS1KRASEGFRHDAC3HDAC4 | |
| SCHEMBL27041260 | 0.91 | SOS1 (0.72) | SOS1KRASEGFRHDAC3HDAC4 | |
| SCHEMBL29985289 | 0.91 | SOS1 (0.72) | SOS1KRASEGFRHDAC3HDAC4 | |
| SCHEMBL29486831 | 0.91 | SOS1 (0.72) | SOS1KRASEGFRHDAC3HDAC4 | |
| SCHEMBL27041275 | 0.91 | SOS1 (0.72) | SOS1KRASEGFRHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | SOS1 1/4885KRAS 143/4885EGFR 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.